TABLE 3.
Overall exercise capacity VO2 peak |
Cardiovascular function HR peak |
Pulmonary function VE/VCO2 slope |
Breathing economy VE/VO2 peak |
|||||
R | p | R | p | R | p | R | p | |
BMI | −0.042 | 0.498 | −0.198 | 0.039 | −0.046 | 0.638 | −0.301 | 0.002 |
FVC | 0.383 | <0.001 | 0.212 | 0.043 | 0.204 | 0.056 | 0.165 | 0.118 |
ALSFRS-R | 0.475 | <0.001 | 0.405 | <0.001 | −0.233 | 0.017 | −0.063 | 0.517 |
UMN | −0.122 | 0.207 | −0.062 | 0.520 | 0.148 | 0.131 | 0.031 | 0.751 |
LMN | −0.229 | 0.016 | −0.087 | 0.368 | 0.325 | 0.001 | 0.199 | 0.039 |
KCSS | −0.390 | <0.001 | −0.325 | 0.001 | 0.077 | 0.434 | 0.028 | 0.770 |
NfL | −0.344 | 0.079 | −0.256 | 0.198 | 0.158 | 0.442 | −0.045 | 0.825 |
ΔFS | −0.433 | <0.001 | −0.430 | <0.001 | 0.138 | 0.162 | −0.031 | 0.751 |
The p-value is based on Spearman’s correlation analysis. p < 0.05 is indicated in bold.
CPET, cardiopulmonary exercise testing; ALS, amyotrophic lateral sclerosis; VO2, oxygen consumption; HR, heart rate; VE, minute ventilation; VCO2, carbon dioxide production; BMI, body mass index; FVC, forced vital capacity; ALSFRS-R, ALS Functional Rating Scale-Revised; UMN, upper motor neuron; LMN, lower motor neuron; KCSS, King’s College Staging System; NfL, neurofilament light chain; ΔFS, (48-[ALSFRS-R])/disease duration from symptom onset to the CPET assessment.